| Similar Articles |
|---|
 |
The Motley Fool
October 30, 2008
Brian Orelli |
Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return.   |
The Motley Fool
February 22, 2011
Brian Orelli |
Biogen and Elan's Growing Problem More cases of potentially lethal PML. |
The Motley Fool
June 30, 2009
Brian Orelli |
Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits. |
The Motley Fool
October 20, 2009
Brian Orelli |
All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug. |
The Motley Fool
July 8, 2008
Brian Orelli |
Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note. |
The Motley Fool
January 12, 2010
Brian Orelli |
Tysabri: It's a Blockbuster! Yawn. So What? Is it really a big deal that Tysabri finally achieved blockbuster status? |
The Motley Fool
March 26, 2009
Brian Orelli |
R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
October 26, 2009
Brian Orelli |
For Tysabri, 23 Is 10 Too Many The side effect rate is important. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
October 27, 2010
Brian Orelli |
Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan. |
The Motley Fool
April 17, 2009
Brian Orelli |
When Revenue Trumps Earnings Biogen grows earnings, but what does that say about the future? |
The Motley Fool
February 10, 2009
Brian Orelli |
Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma. |
The Motley Fool
November 24, 2004
Charly Travers |
A Blockbuster Drug Gains Approval Biogen IDEC and Elan announced that Tysabri had been approved by the FDA for the treatment of muliple sclerosis (MS). Tysabri has long been regarded as a drug that will generate a whopping level of sales. |
The Motley Fool
January 25, 2010
Brian Orelli |
Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri. |
The Motley Fool
July 17, 2009
Brian Orelli |
Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
October 22, 2008
Brian Orelli |
Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places. |
The Motley Fool
December 5, 2007
Brian Orelli |
Early Bird Gets the MS Worm Teva's multiple sclerosis drug COPAXONE performs well in a label-expanding trial. |
The Motley Fool
February 2, 2011
Brian Orelli |
A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker. |
The Motley Fool
January 21, 2011
Brian Orelli |
Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down. |
The Motley Fool
October 1, 2009
Anders Bylund |
Why I'm Invested in Tysabri and Elan This Motley Fool analyst has investigated Elan both as an investor and a patient. What's his verdict on the company? |
The Motley Fool
February 7, 2008
Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. |
The Motley Fool
February 11, 2010
Brian Orelli |
Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
October 18, 2007
Brian Lawler |
Genzyme Shows Off a Drug Candidate A top compound in development could become an important MS treatment. |
The Motley Fool
November 26, 2010
Anders Bylund |
Teva Is Running Scared A personal take on the MS medicine market: A little bit of marketing spin keeps the doctor away, but too much makes you a jerk. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
May 5, 2010
Brian Orelli |
Teva's Double-Edged Sword Nice quarter, but where will future growth come from? |
The Motley Fool
August 10, 2011
Brian Orelli |
A Jab a Month Is All We Ask Biogen and Abbott's new long-acting multiple sclerosis drug works, but it has side effects. |
The Motley Fool
September 4, 2009
Brian Orelli |
The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up. |
The Motley Fool
July 23, 2008
Brian Lawler |
No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results. |
The Motley Fool
July 30, 2008
Brian Orelli |
Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest. |
The Motley Fool
February 28, 2006
Stephen D. Simpson |
Still Waiting for Teva to Stumble This leading Israeli generics firm hasn't seen a stock pullback of any consequence since mid- to late 2004. And while fourth-quarter results weren't fabulous, they were good enough given the circumstances |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
December 9, 2010
Brian Orelli |
Here Comes Another Oral MS Drug Good for Teva, bad for the rest. |
The Motley Fool
February 6, 2009
Brian Orelli |
Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board. |
The Motley Fool
October 27, 2011
Brian Orelli |
DEFINE First, CONFIRM Second, See Shares Rise 60% Third Biogen CONFIRMs it has a new blockbuster drug and shares jump. |
The Motley Fool
September 23, 2010
Brian Orelli |
A Blockbuster in Due Time Novartis' new multiple sclerosis drug, Gilenya, isn't king yet. |
The Motley Fool
February 18, 2009
Brian Orelli |
Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens. |
The Motley Fool
April 22, 2011
MedCity News |
Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments. |
The Motley Fool
August 26, 2008
Brian Lawler |
FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs. |
The Motley Fool
October 24, 2007
Brian Lawler |
Biogen's Brisk Business Following a rumor-filled and busy couple of weeks, Biogen releases its third-quarter financial results. |
The Motley Fool
June 3, 2010
Brian Orelli |
When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors. |
The Motley Fool
April 23, 2009
Brian Orelli |
Elan's Strategic Uncertainty Elan has nothing new to report yet on the strategic review that Citigroup is preparing for them. |
The Motley Fool
March 1, 2005
Stephen D. Simpson |
When Bad News Is Good News The withdrawal of Tysabri is terrible news for Biogen Idec and Elan, but other firms may benefit. |
The Motley Fool
February 13, 2008
Brian Orelli |
Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted. |
The Motley Fool
September 22, 2010
Jordan DiPietro |
A Huge Victory for Novartis MS oral drug is approved. |
The Motley Fool
August 1, 2011
Brian Orelli |
Bravo? Not Really. Teva's oral multiple sclerosis drug, laquinimod, fails to impress. |
